Karim Kristin E, Wu Caroline M, Giladi Aviram M, Murphy Michael S
Curtis National Hand Center, MedStar Union Memorial Hospital, Baltimore, MD.
Curtis National Hand Center, MedStar Union Memorial Hospital, Baltimore, MD.
J Hand Surg Am. 2021 May;46(5):409-415. doi: 10.1016/j.jhsa.2021.01.006.
Orthobiologic agents are used as innovative adjuvant therapy to treat common upper-extremity pathology, including carpal tunnel syndrome, de Quervain tenosynovitis, and distal radius fractures. In this article, we perform a narrative review and evaluate current literature on orthobiologics in the upper extremity. Orthobiologics evaluated include bone morphogenetic proteins, platelet-rich plasma, bone marrow aspirate concentrate, mesenchymal stem cells, and amniotic membrane. Studies selected include randomized control trials, case studies, and animal studies. Although there is some clinical evidence regarding the use of orthobiologic agents in the treatment of shoulder, elbow, and sports injuries, there is a paucity of literature regarding their use to treat pathology of the hand and wrist. Further investigation is necessary to determine their effectiveness and therapeutic value in treatment of upper extremity injuries.
矫形生物制剂被用作创新辅助疗法，以治疗常见的上肢疾病，包括腕管综合征、桡骨茎突狭窄性腱鞘炎和桡骨远端骨折。在本文中，我们进行了一项叙述性综述，并评估了当前关于上肢矫形生物制剂的文献。所评估的矫形生物制剂包括骨形态发生蛋白、富血小板血浆、骨髓抽吸浓缩物、间充质干细胞和羊膜。所选研究包括随机对照试验、病例研究和动物研究。尽管有一些关于矫形生物制剂用于治疗肩部、肘部和运动损伤的临床证据，但关于其用于治疗手部和腕部疾病的文献却很少。有必要进一步研究以确定它们在治疗上肢损伤中的有效性和治疗价值。
